Blood Cancer Treatment Navigator
Not "what is blood cancer" — but what should I do next? Find your treatment path based on diagnosis, line of therapy, budget, and urgency. CAR-T, transplant, NK cells, trials — compare 7 countries.
Select Your Blood Cancer Type
Each card shows the critical treatment decision point and best destination routes for your specific diagnosis.
DLBCL
Diffuse Large B-Cell Lymphoma — the most common aggressive lymphoma
B-ALL
B-Cell Acute Lymphoblastic Leukemia — high cure rate with CAR-T
Multiple Myeloma
BCMA-targeted CAR-T and bispecific antibodies are transforming outcomes
AML
Acute Myeloid Leukemia — transplant and trial-centric pathways
CLL / SLL
Chronic Lymphocytic Leukemia — targeted therapy-first approach
Follicular Lymphoma
Indolent but incurable — CAR-T for transformed or refractory disease
Hodgkin Lymphoma
Highly curable — immunotherapy and transplant for relapsed cases
T-Cell Lymphomas
Rare and challenging — clinical trials are the primary pathway
MDS
Myelodysplastic Syndromes — transplant is the only curative option
Navigate by Treatment Need
Already know your treatment direction? Find the optimal destination for each pathway.
I'm a CAR-T Candidate
For patients with relapsed/refractory DLBCL, B-ALL, Myeloma, or FL who have failed 2+ lines of therapy and have adequate organ function (ECOG 0-2).
- Confirm CD19/BCMA expression
- Check organ function & ECOG status
- Compare FDA vs trial CAR-T products
I Need a Transplant
For AML, high-risk MDS, relapsed Hodgkin, or consolidative transplant after CAR-T. Allogeneic transplant with matched donor or haploidentical options.
- HLA typing & donor search
- Disease status: CR/PR required
- Compare myeloablative vs RIC protocols
I'm Seeking a Clinical Trial
For patients who have exhausted standard options or have rare subtypes (T-cell lymphoma, double-refractory disease). Access novel CAR-T, bispecific antibodies, and targeted agents.
- Molecular profiling (NGS panel)
- List all prior therapies & responses
- Check trial eligibility criteria (ECOG, organ function)
I'm Relapsed/Refractory
For patients whose disease progressed after standard therapy. This is the highest-urgency pathway requiring rapid decision-making between CAR-T, transplant, or trial access.
- Repeat biopsy to confirm relapse
- Re-assess molecular markers
- Urgent second opinion within 48 hours
I'm Newly Diagnosed
For patients at the beginning of their journey. Understanding whether standard therapy is sufficient or if early trial/CAR-T consideration is warranted based on risk stratification.
- Complete molecular profiling
- Risk stratification (IPI, R-IPI, cytogenetics)
- Second opinion on treatment plan
Blood Cancer: Country Comparison
Each country has a distinct role in the blood cancer treatment ecosystem. Choose based on your priority.
China
South Korea
India
Germany
Turkey
Which Path Fits Me?
Four common scenarios. Find the one that matches your situation and see the recommended next step.
Relapsed After Chemo
You've completed first-line therapy but PET-CT shows residual or progressive disease. Time to evaluate CAR-T eligibility or second-line salvage.
Double-Refractory Disease
You've progressed on BTK inhibitors, IMiDs, PIs, or anti-CD38. Standard options are exhausted. Clinical trials are your primary pathway.
Newly Diagnosed, High-Risk
Your pathology shows high-risk features (double-hit lymphoma, complex karyotype AML, high-risk MDS). Early planning for transplant or trial is critical.
Seeking Better Access Abroad
CAR-T, novel bispecific antibodies, or specific targeted agents are not approved or available where you live. Cross-border access is your solution.
Blood Cancer Decision Matrix
Complete scan: diagnosis × treatment × country × budget × urgency × next step.
| Diagnosis | Treatment | Best Country | Budget | Urgency | Next Step |
|---|---|---|---|---|---|
| DLBCL (relapsed) | CAR-T | 🇨🇳 China | $30K-$80K | High | CD19 expression check |
| DLBCL (relapsed) | CAR-T | 🇰🇷 Korea | $250K-$350K | Medium | FDA-approved products |
| B-ALL (R/R) | CAR-T | 🇨🇳 China | $30K-$80K | Critical | CD19 CAR-T within 2-4w |
| B-ALL (R/R) | CAR-T | 🇺🇸 USA | $373K-$475K | Slow | Kymriah (tisagenlecleucel) |
| Myeloma (3L+) | BCMA CAR-T | 🇨🇳 China | $30K-$80K | Medium | BCMA expression required |
| Myeloma (3L+) | BCMA CAR-T | 🇺🇸 USA | $400K+ | Slow | Carvykti or Abecma |
| AML (high-risk) | Transplant | 🇩🇪 Germany | $150K-$250K | Critical | HLA typing urgently |
| AML (relapsed) | Trial | 🇨🇳 China | $40K-$80K | Critical | FLT3/IDH mutation testing |
| FL (POD24) | CAR-T | 🇨🇳 China | $30K-$80K | Medium | Confirm transformation |
| T-Cell Lymphoma | Trial | 🇨🇳 China | $40K-$80K | High | CD7 CAR-T trials |
| MDS (high-risk) | Transplant | 🇩🇪 Germany | $150K-$250K | High | Donor search + IPSS-R |
| All Blood Cancers | Second Opinion | 🌍 All | FREE | 48h | Submit records |
Navigation Tools & Resources
Practical tools to move from decision to action.
Required Documents Checklist
Everything you need to submit for a blood cancer case review.
- Pathology report (IHC, flow cytometry)
- Cytogenetics & FISH report
- Recent PET-CT / CT (DICOM)
- Complete treatment history (all lines)
- Current blood counts & ECOG status
Timeline Estimator
How fast can you access treatment based on your diagnosis and destination?
- China: 2-4 weeks (CAR-T trials)
- India/Turkey: 4-8 weeks
- Korea/Germany: 6-10 weeks
- USA: 8-12 weeks (standard)
- Second opinion: 48 hours
Country Comparison Tool
Side-by-side comparison of cost, wait time, regulatory status, and language support.
- CAR-T cost: $30K (China) to $475K (USA)
- FDA-approved: USA, Korea, Germany
- Trial-based: China, India
- Language: EN, AR, TR, FA, RU, ZH, KO
Second Opinion Checklist
What to ask when getting a second opinion for blood cancer.
- Am I eligible for CAR-T or transplant?
- What trials match my molecular profile?
- Which country is best for my specific case?
- What's the realistic timeline & budget?
- What follow-up care will I need?
Disclaimer: This is a decision-support tool, not medical advice. All treatment decisions are made by licensed physicians at partner institutions. Read our full Legal Framework →
Blood Cancer Treatment FAQ
Common questions from blood cancer patients navigating treatment decisions.
CAR-T eligibility depends on: specific diagnosis (DLBCL, B-ALL, Myeloma, FL have approved products), prior treatment lines (typically 2+), organ function (liver, kidney, heart), performance status (ECOG 0-2), and CD19/BCMA expression. China's 700+ trials expand eligibility to more subtypes. Submit your records for a free assessment within 48 hours.
Not always. CAR-T is increasingly used as standalone therapy, especially for DLBCL and B-ALL. The decision depends on MRD status post-CAR-T, disease subtype, depth of response, and patient fitness. Some patients benefit from consolidative transplant. Our partner hematologists provide evidence-based recommendations based on your specific response.
China: 2-4 weeks from referral to infusion (14-21 day manufacturing). India/Turkey: 4-8 weeks. Korea/Germany: 6-10 weeks. USA: 8-12 weeks. For rapidly progressive disease (blast count rising, LDH increasing), expedited pathways exist. Time from leukapheresis to CAR-T infusion is the critical window — bridging therapy may be needed.
Published outcomes are comparable across major centers. China's high volume (700+ trials, thousands of patients treated) provides extensive real-world data. US FDA-approved products have the longest follow-up (5+ years for ZUMA-1). Germany and Korea offer premium care with strong regulatory oversight. The "best" country depends on your specific diagnosis, product access, and personal circumstances.
Options include: clinical trials in China ($30K-$80K), treatment in India ($40K-$90K), manufacturer patient assistance programs (US only), hospital payment plans, medical loans, and charitable foundations. Our coordination is free — we help you find the most cost-effective path without compromising on quality. Submit your case for a personalized cost comparison.
Submit through our secure HIPAA-aligned portal. Required: pathology report with IHC/flow cytometry, cytogenetics/FISH, recent PET-CT/CT (DICOM), complete treatment history (all lines with dates and responses), current blood counts, and ECOG performance status. Our hematology team pre-screens within 48 hours and matches you with appropriate pathways and institutions.
Ready to Find Your Blood Cancer Treatment Path?
Submit your case for a free, no-obligation assessment. Our hematology-oncology team will match your diagnosis, treatment history, and goals with the optimal destination and pathway within 48 hours.
Submit Your Case NowFree • Confidential • 48-Hour Response • No Obligation